Therapeutic strategies to remodel immunologically cold tumors.

"Conflicts of interest PJN received research grants from Roche/Genentech, BMS, Allergan, Compugen and Juno/Celgene, outside the submitted work. JD reports research support from Roche Genentech, Lilly, Astra Zeneca, BeiGene, Novartis, Bristol‐Myers Squibb and GlaxoSmithKline, and consulting fees from Amgen, Eisai and Pierre‐Fabre. The authors have no other conflicts of interest to declare."

"The authors acknowledge long‐term funding support from the National Health and Medical Research Council (NHMRC) of Australia and Cancer Council Victoria, in the form of many Program, Project, Venture and Fellowship grants over the past 20 years. JAT and PJN are also very grateful to the Peter MacCallum Cancer Foundation for generous philanthropic support. In particular, JAT is a Rosie Lew Fellow of the Foundation. SW thanks the Hudson Institute of Medical Research for the support. The figures included in this paper were created with BioRender.com."